| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A randomized trial of deep-brain stimulation for Parkinson's disease.
|
N Engl J Med
|
2006
|
8.12
|
|
2
|
Recombinant human erythropoietin in the treatment of acute ischemic stroke.
|
Stroke
|
2009
|
5.28
|
|
3
|
Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications.
|
Neurology
|
2013
|
2.99
|
|
4
|
Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice.
|
PLoS One
|
2010
|
2.15
|
|
5
|
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
|
J Clin Oncol
|
2003
|
2.14
|
|
6
|
Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial.
|
Lancet Neurol
|
2011
|
2.12
|
|
7
|
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD).
|
J Neurol
|
2008
|
1.62
|
|
8
|
Reliability of brain CT evaluation by stroke neurologists in telemedicine.
|
Neurology
|
2012
|
1.54
|
|
9
|
Autonomic function and cerebral autoregulation in patients undergoing carotid endarterectomy.
|
Circ J
|
2010
|
1.45
|
|
10
|
Olfactory loss may be a first sign of idiopathic Parkinson's disease.
|
Mov Disord
|
2007
|
1.41
|
|
11
|
Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice.
|
Sci Rep
|
2012
|
1.36
|
|
12
|
Non-motor dysfunction in Parkinson's disease.
|
Parkinsonism Relat Disord
|
2007
|
1.35
|
|
13
|
Adherence to antiparkinson medication in a multicenter European study.
|
Mov Disord
|
2009
|
1.34
|
|
14
|
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
|
Arch Neurol
|
2007
|
1.34
|
|
15
|
Mitochondrial cytopathies.
|
J Neurol
|
2003
|
1.28
|
|
16
|
Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease.
|
J Neurol
|
2010
|
1.24
|
|
17
|
EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
|
Mov Disord
|
2014
|
1.23
|
|
18
|
The stem cell marker prominin-1/CD133 on membrane particles in human cerebrospinal fluid offers novel approaches for studying central nervous system disease.
|
Stem Cells
|
2007
|
1.21
|
|
19
|
Genes associated with Parkinson syndrome.
|
J Neurol
|
2008
|
1.21
|
|
20
|
Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT.
|
Mov Disord
|
2004
|
1.09
|
|
21
|
Transdermal rotigotine for the perioperative management of Parkinson's disease.
|
J Neural Transm (Vienna)
|
2010
|
1.08
|
|
22
|
Different odor tests contribute differently to the evaluation of olfactory loss.
|
Chem Senses
|
2007
|
1.05
|
|
23
|
Loss of nocturnal blood pressure fall in various extrapyramidal syndromes.
|
Mov Disord
|
2009
|
1.02
|
|
24
|
Depression and Parkinson's disease.
|
J Neurol
|
2004
|
1.02
|
|
25
|
Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.
|
J Neurol Sci
|
2006
|
1.02
|
|
26
|
Primary skin fibroblasts as a model of Parkinson's disease.
|
Mol Neurobiol
|
2012
|
1.01
|
|
27
|
Utility of the WHO-Five Well-being Index as a screening tool for depression in Parkinson's disease.
|
Mov Disord
|
2010
|
1.00
|
|
28
|
A longitudinal study of olfactory function in patients with idiopathic Parkinson's disease.
|
J Neurol
|
2008
|
1.00
|
|
29
|
Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.
|
J Neurol Sci
|
2009
|
1.00
|
|
30
|
Cardiovascular autonomic dysfunction in Parkinson's disease.
|
J Neurol Sci
|
2009
|
0.99
|
|
31
|
Biopsies of olfactory epithelium in patients with Parkinson's disease.
|
Mov Disord
|
2009
|
0.99
|
|
32
|
Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study.
|
J Neurooncol
|
2008
|
0.97
|
|
33
|
Olfactory dysfunction as a diagnostic marker for Parkinson's disease.
|
Expert Rev Neurother
|
2009
|
0.95
|
|
34
|
Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma.
|
Neuro Oncol
|
2010
|
0.95
|
|
35
|
Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma.
|
Ann Neurol
|
2010
|
0.93
|
|
36
|
Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.
|
J Neuropsychiatry Clin Neurosci
|
2005
|
0.91
|
|
37
|
Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
|
J Neural Transm (Vienna)
|
2009
|
0.90
|
|
38
|
Olfactory training in patients with Parkinson's disease.
|
PLoS One
|
2013
|
0.89
|
|
39
|
Olfactory loss in Parkinson's disease.
|
Parkinsons Dis
|
2011
|
0.89
|
|
40
|
Improved odor sensitivity in attention-deficit/hyperactivity disorder.
|
Biol Psychiatry
|
2008
|
0.88
|
|
41
|
Expression and localization of nuclear proteins in autosomal-dominant Emery-Dreifuss muscular dystrophy with LMNA R377H mutation.
|
BMC Cell Biol
|
2004
|
0.88
|
|
42
|
Iron-dependent functions of mitochondria--relation to neurodegeneration.
|
J Neural Transm (Vienna)
|
2010
|
0.88
|
|
43
|
Utility of measuring vitamin B12 and its active fraction, holotranscobalamin, in neurological vitamin B12 deficiency syndromes.
|
J Neurol
|
2010
|
0.88
|
|
44
|
Sleep and non-motor symptoms in Parkinson's disease.
|
J Neural Transm (Vienna)
|
2013
|
0.87
|
|
45
|
Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease.
|
Parkinsonism Relat Disord
|
2012
|
0.87
|
|
46
|
Prediction of outcome in neurogenic oropharyngeal dysphagia within 72 hours of acute stroke.
|
J Stroke Cerebrovasc Dis
|
2011
|
0.86
|
|
47
|
Health-related quality of life in multiple system atrophy and progressive supranuclear palsy.
|
Neurodegener Dis
|
2011
|
0.86
|
|
48
|
Dementia in idiopathic Parkinson's syndrome.
|
J Neurol
|
2004
|
0.85
|
|
49
|
Beyond tremor and rigidity: non-motor features of Parkinson's disease.
|
J Neural Transm (Vienna)
|
2009
|
0.85
|
|
50
|
Cardiovascular autonomic testing in extrapyramidal disorders.
|
J Neurol Sci
|
2011
|
0.84
|
|
51
|
Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes.
|
Mov Disord
|
2010
|
0.84
|
|
52
|
Autonomic dysfunction in patients with progressive supranuclear palsy.
|
Mov Disord
|
2008
|
0.84
|
|
53
|
Mitochondrial dysfunction in Parkinson's disease--revisited.
|
Neurol Neurochir Pol
|
2007
|
0.83
|
|
54
|
Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis.
|
Atheroscler Suppl
|
2009
|
0.83
|
|
55
|
Extrapyramidal symptoms in Wilson's disease are associated with olfactory dysfunction.
|
Mov Disord
|
2006
|
0.83
|
|
56
|
Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.
|
Parkinsonism Relat Disord
|
2007
|
0.83
|
|
57
|
Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.
|
BMC Neurol
|
2011
|
0.82
|
|
58
|
Static posturography in aging and Parkinson's disease.
|
Front Aging Neurosci
|
2012
|
0.82
|
|
59
|
Different diagnostic criteria for Parkinson disease: what are the pitfalls?
|
J Neural Transm (Vienna)
|
2013
|
0.82
|
|
60
|
The exceptional properties of 9-methyl-beta-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects.
|
J Neurochem
|
2010
|
0.82
|
|
61
|
Association of sleep apnea with clinically silent microvascular brain tissue changes in acute cerebral ischemia.
|
J Neurol
|
2013
|
0.82
|
|
62
|
Neurotoxic mechanisms of 2,9-dimethyl-beta-carbolinium ion in primary dopaminergic culture.
|
J Neurochem
|
2006
|
0.81
|
|
63
|
Effects of rasagiline on olfactory function in patients with Parkinson’s disease.
|
Mov Disord
|
2013
|
0.81
|
|
64
|
Switching and combining of dopamine agonists.
|
J Neurol
|
2004
|
0.81
|
|
65
|
Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report.
|
Mov Disord
|
2008
|
0.81
|
|
66
|
Chocolate consumption is increased in Parkinson's disease. Results from a self-questionnaire study.
|
J Neurol
|
2009
|
0.81
|
|
67
|
Whole blood genome-wide expression profiling and network analysis suggest MELAS master regulators.
|
Neurol Res
|
2011
|
0.80
|
|
68
|
Emergency transfer of acute stroke patients within the East Saxony telemedicine stroke network: a descriptive analysis.
|
Int J Stroke
|
2013
|
0.79
|
|
69
|
Computed tomographically-controlled injection of botulinum toxin into the longus colli muscle in severe anterocollis.
|
Mov Disord
|
2004
|
0.79
|
|
70
|
Trigonometric regressive spectral analysis reliably maps dynamic changes in baroreflex sensitivity and autonomic tone: the effect of gender and age.
|
PLoS One
|
2010
|
0.79
|
|
71
|
Early versus delayed initiation of pharmacotherapy in Parkinson's disease.
|
Drugs
|
2014
|
0.79
|
|
72
|
Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
|
Neurology
|
2013
|
0.78
|
|
73
|
Determination of baroreflex sensitivity during the modified Oxford maneuver by trigonometric regressive spectral analysis.
|
PLoS One
|
2011
|
0.78
|
|
74
|
Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
|
J Neural Transm (Vienna)
|
2010
|
0.78
|
|
75
|
Microcurrent transcutaneous electric nerve stimulation in painful diabetic neuropathy: a randomized placebo-controlled study.
|
Pain Med
|
2011
|
0.78
|
|
76
|
Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.
|
Ann Clin Biochem
|
2013
|
0.78
|
|
77
|
Early sleep apnea screening on a stroke unit is feasible in patients with acute cerebral ischemia.
|
J Neurol
|
2012
|
0.78
|
|
78
|
Olfactory FMRI in patients with Parkinson's disease.
|
Front Integr Neurosci
|
2010
|
0.78
|
|
79
|
[Teaching of psychosomatic medicine and psychotherapy as an element of the Dresden DIPOL-Curriculum -- the PBL-course "Nervous system" and psyche].
|
Psychother Psychosom Med Psychol
|
2003
|
0.78
|
|
80
|
Prefrontal cortex dysfunction and depression in atypical parkinsonian syndromes.
|
Mov Disord
|
2007
|
0.78
|
|
81
|
Selective hyposmia in Parkinson's disease?
|
J Neurol
|
2013
|
0.78
|
|
82
|
Hypoglycemia-induced choreoathetosis associated with hyperintense basal ganglia lesions in T1-weighted brain MRI.
|
Mov Disord
|
2010
|
0.77
|
|
83
|
Analysis of HLA class I and II alleles in sporadic inclusion-body myositis.
|
J Neurol
|
2003
|
0.77
|
|
84
|
Metabolic patterns in meningiomas.
|
J Neurooncol
|
2003
|
0.77
|
|
85
|
Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia - a randomized, double-blind, double-dummy crossover study.
|
Br J Clin Pharmacol
|
2014
|
0.77
|
|
86
|
Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug?
|
Expert Rev Neurother
|
2011
|
0.77
|
|
87
|
[Interdisciplinarity and chronic pain therapy--implementation of a new Interdisciplinary Center at the University Hospital Dresden on the basis of an integrated health care contract].
|
Z Arztl Fortbild Qualitatssich
|
2007
|
0.76
|
|
88
|
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
|
Mov Disord
|
2007
|
0.76
|
|
89
|
Autonomic dysfunction in different subtypes of multiple system atrophy.
|
Mov Disord
|
2008
|
0.76
|
|
90
|
Persistent organic personality change as rare psychiatric manifestation of MELAS syndrome.
|
J Neurol
|
2003
|
0.76
|
|
91
|
Lewy body dementia and Parkinson's disease with dementia.
|
J Neurol
|
2008
|
0.76
|
|
92
|
Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes.
|
Mov Disord
|
2007
|
0.76
|
|
93
|
LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients.
|
Atherosclerosis
|
2010
|
0.75
|
|
94
|
Dementia with Lewy bodies.
|
J Neurol Sci
|
2006
|
0.75
|
|
95
|
Treatment of dysautonomia in extrapyramidal disorders.
|
Ther Adv Neurol Disord
|
2010
|
0.75
|
|
96
|
Reduced body mass index in Parkinson's disease: contribution of comorbid depression.
|
J Nerv Ment Dis
|
2013
|
0.75
|
|
97
|
Olfactory function in patients with and without temporal lobe resection.
|
Epilepsy Behav
|
2012
|
0.75
|
|
98
|
Hemiplegic migraine with reversible cerebral vasoconstriction caused by ATP1A2 mutations.
|
J Neurol
|
2013
|
0.75
|
|
99
|
"Atraumatic" Sprotte needle reduces the incidence of post-lumbar puncture headaches.
|
Neurology
|
2002
|
0.75
|
|
100
|
9-Methyl-beta-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture.
|
Neurochem Int
|
2007
|
0.75
|
|
101
|
Reversal of the neurological deficit in acute stroke with the signal of efficacy trial of auto-BPAP to limit damage from suspected sleep apnea (Reverse-STEAL): study protocol for a randomized controlled trial.
|
Trials
|
2013
|
0.75
|
|
102
|
Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease.
|
Int J Neurosci
|
2011
|
0.75
|
|
103
|
Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection").
|
Neurotherapeutics
|
2015
|
0.75
|
|
104
|
Levodopa in the treatment of Parkinson's disease: current controversies.
|
Mov Disord
|
2005
|
0.75
|
|
105
|
[Sensory and autonomic small fiber neuropathy].
|
MMW Fortschr Med
|
2015
|
0.75
|
|
106
|
The dopaminergic system: an everlasting challenge. Editorial.
|
J Neurol
|
2006
|
0.75
|
|
107
|
Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with ¹⁸F-dopa brain PET in normal controls and patients with Parkinson's disease.
|
Eur J Nucl Med Mol Imaging
|
2011
|
0.75
|
|
108
|
Cost-of-illness in multiple system atrophy and progressive supranuclear palsy.
|
J Neurol
|
2011
|
0.75
|
|
109
|
Idiopathic Parkinson's syndrome. Preface.
|
J Neurol Sci
|
2011
|
0.75
|
|
110
|
[Epilepsy: recommendations for daily activities].
|
MMW Fortschr Med
|
2011
|
0.75
|
|
111
|
Accurate detection of Parkinson's disease in tremor syndromes using olfactory testing.
|
Eur Neurol
|
2014
|
0.75
|
|
112
|
JNT Special Issue MDPD Congress, Berlin 2012.
|
J Neural Transm (Vienna)
|
2013
|
0.75
|
|
113
|
Parkinson's Disease and Gastrointestinal Non Motor Symptoms: Diagnostic and Therapeutic Options - A Practise Guide.
|
J Parkinsons Dis
|
2015
|
0.75
|
|
114
|
Comparable Neuroprotective Effects of Pergolide and Pramipexole on Ferrous Sulfate-Induced Dopaminergic Cell Death in Cell Culture.
|
CNS Neurol Disord Drug Targets
|
2016
|
0.75
|
|
115
|
Preface to special issue on Mental Dysfunction in Parkinson's Disease.
|
J Neurol Sci
|
2009
|
0.75
|
|
116
|
Treatment of dysautonomia in extrapyramidal disorders.
|
J Neurol
|
2011
|
0.75
|
|
117
|
Association of mitochondrial disorders with lymphoid malignancies.
|
Mitochondrion
|
2007
|
0.75
|
|
118
|
Comparison of chocolate to cacao-free white chocolate in Parkinson's disease: a single-dose, investigator-blinded, placebo-controlled, crossover trial.
|
J Neurol
|
2012
|
0.75
|
|
119
|
Neuroprotective effect of rotigotine against complex I inhibitors, MPP⁺ and rotenone, in primary mesencephalic cell culture.
|
Folia Neuropathol
|
2014
|
0.75
|
|
120
|
Parkinson's disease: a multi-faceted disease.
|
J Neurol
|
2011
|
0.75
|